UA67748C2 - Активний інгредієнт для виробництва лікарського засобу для інгібування резорбції кісткової тканини у людини (варіанти) - Google Patents

Активний інгредієнт для виробництва лікарського засобу для інгібування резорбції кісткової тканини у людини (варіанти) Download PDF

Info

Publication number: UA67748C2
Authority: UA; Ukraine
Prior art keywords: alendronic acid; alendronate; active ingredient; week; pharmaceutically acceptable
Prior art date: 1997-07-22

Application number

UA2000020982A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Анастасія Г. Дейфотіс

ІІ Сантора Артур К.

А. Джон Йейтс

Original Assignee

Мерк Енд Ко., Інк.

Мерк Энд Ко., Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-22

Filing date

1998-07-17

Publication date

2004-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43743642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA67748(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-08-20 Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en

1997-08-22 Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en

1998-07-17 Application filed by Мерк Енд Ко., Інк., Мерк Энд Ко., Инк. filed Critical Мерк Енд Ко., Інк.

1998-07-17 Priority claimed from PCT/US1998/014796 external-priority patent/WO1999004773A2/en

2004-07-15 Publication of UA67748C2 publication Critical patent/UA67748C2/uk

Links

208000006386 Bone Resorption Diseases 0.000 title claims abstract description 30
230000024279 bone resorption Effects 0.000 title claims abstract description 30
230000002401 inhibitory effect Effects 0.000 title claims abstract description 14
239000004480 active ingredient Substances 0.000 title claims description 13
239000008194 pharmaceutical composition Substances 0.000 title abstract description 4
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims abstract description 87
241000124008 Mammalia Species 0.000 claims abstract description 27
230000000694 effects Effects 0.000 claims description 61
238000011282 treatment Methods 0.000 claims description 54
239000003814 drug Substances 0.000 claims description 45
208000001132 Osteoporosis Diseases 0.000 claims description 41
229960004343 alendronic acid Drugs 0.000 claims description 41
229940079593 drug Drugs 0.000 claims description 39
230000002265 prevention Effects 0.000 claims description 31
210000000988 bone and bone Anatomy 0.000 claims description 26
239000000203 mixture Substances 0.000 claims description 24
239000008297 liquid dosage form Substances 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 22
DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 claims description 14
239000002775 capsule Substances 0.000 claims description 4
229940126601 medicinal product Drugs 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims 5
239000003795 chemical substances by application Substances 0.000 claims 4
229940122361 Bisphosphonate Drugs 0.000 abstract description 82
150000004663 bisphosphonates Chemical class 0.000 abstract description 80
238000000034 method Methods 0.000 abstract description 74
229940062527 alendronate Drugs 0.000 abstract description 57
-1 etridronate Chemical compound 0.000 abstract description 21
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract description 13
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 abstract description 10
229940089617 risedronate Drugs 0.000 abstract description 10
229940019375 tiludronate Drugs 0.000 abstract description 9
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 abstract description 6
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 abstract description 6
229960002286 clodronic acid Drugs 0.000 abstract description 6
239000003485 histamine H2 receptor antagonist Substances 0.000 abstract description 6
229940015872 ibandronate Drugs 0.000 abstract description 6
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 abstract description 5
229940046231 pamidronate Drugs 0.000 abstract description 5
238000002560 therapeutic procedure Methods 0.000 abstract description 5
230000002496 gastric effect Effects 0.000 abstract description 4
229950006971 incadronic acid Drugs 0.000 abstract description 4
LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 abstract description 4
230000002411 adverse Effects 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 abstract description 2
241001465754 Metazoa Species 0.000 description 39
210000003238 esophagus Anatomy 0.000 description 37
210000001035 gastrointestinal tract Anatomy 0.000 description 31
239000003826 tablet Substances 0.000 description 29
210000004051 gastric juice Anatomy 0.000 description 24
230000002354 daily effect Effects 0.000 description 20
230000002159 abnormal effect Effects 0.000 description 19
241000282472 Canis lupus familiaris Species 0.000 description 17
239000002253 acid Substances 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
206010061218 Inflammation Diseases 0.000 description 15
230000004054 inflammatory process Effects 0.000 description 15
235000002639 sodium chloride Nutrition 0.000 description 14
239000000126 substance Substances 0.000 description 14
125000004122 cyclic group Chemical group 0.000 description 13
201000010099 disease Diseases 0.000 description 13
210000004876 tela submucosa Anatomy 0.000 description 13
238000011269 treatment regimen Methods 0.000 description 13
238000001802 infusion Methods 0.000 description 11
239000003112 inhibitor Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
208000025865 Ulcer Diseases 0.000 description 9
230000000670 limiting effect Effects 0.000 description 9
239000012188 paraffin wax Substances 0.000 description 9
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 8
241000282412 Homo Species 0.000 description 8
206010065687 Bone loss Diseases 0.000 description 7
206010070818 Oesophageal irritation Diseases 0.000 description 7
201000006549 dyspepsia Diseases 0.000 description 6
210000000981 epithelium Anatomy 0.000 description 6
229940009626 etidronate Drugs 0.000 description 6
210000002784 stomach Anatomy 0.000 description 6
238000001647 drug administration Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
230000036269 ulceration Effects 0.000 description 5
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 4
102000003710 Histamine H2 Receptors Human genes 0.000 description 4
108090000050 Histamine H2 Receptors Proteins 0.000 description 4
206010030216 Oesophagitis Diseases 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000033558 biomineral tissue development Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
208000006881 esophagitis Diseases 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000030991 negative regulation of bone resorption Effects 0.000 description 4
210000002997 osteoclast Anatomy 0.000 description 4
125000000547 substituted alkyl group Chemical group 0.000 description 4
231100000397 ulcer Toxicity 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
229960004276 zoledronic acid Drugs 0.000 description 4
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
208000018522 Gastrointestinal disease Diseases 0.000 description 3
208000010191 Osteitis Deformans Diseases 0.000 description 3
208000027868 Paget disease Diseases 0.000 description 3
206010052306 Periprosthetic osteolysis Diseases 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000000123 anti-resoprtive effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000003203 everyday effect Effects 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
208000027202 mammary Paget disease Diseases 0.000 description 3
238000010992 reflux Methods 0.000 description 3
229960000759 risedronic acid Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 2
125000000923 (C1-C30) alkyl group Chemical group 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000010392 Bone Fractures Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
SKUHWSDHMJMHIW-UHFFFAOYSA-L disodium;[(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)SC1=CC=C(Cl)C=C1 SKUHWSDHMJMHIW-UHFFFAOYSA-L 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
208000024798 heartburn Diseases 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000001788 irregular Effects 0.000 description 2
239000002085 irritant Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
208000005368 osteomalacia Diseases 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000002477 vacuolizing effect Effects 0.000 description 2
230000003313 weakening effect Effects 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
208000028906 Abnormal bone structure Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
208000005489 Esophageal Perforation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010030181 Oesophageal perforation Diseases 0.000 description 1
206010030201 Oesophageal ulcer Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
125000005340 bisphosphate group Chemical group 0.000 description 1
230000037182 bone density Effects 0.000 description 1
230000018678 bone mineralization Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
208000028299 esophageal disease Diseases 0.000 description 1
208000019064 esophageal ulcer Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
229960003174 lansoprazole Drugs 0.000 description 1
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000000465 moulding Methods 0.000 description 1
210000005088 multinucleated cell Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000000025 natural resin Substances 0.000 description 1
PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
229950010733 neridronic acid Drugs 0.000 description 1
229960004872 nizatidine Drugs 0.000 description 1
SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
235000020939 nutritional additive Nutrition 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229940032666 tiludronate disodium Drugs 0.000 description 1
229960005324 tiludronic acid Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
239000001993 wax Substances 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2000020982A 1997-07-22 1998-07-17 Активний інгредієнт для виробництва лікарського засобу для інгібування резорбції кісткової тканини у людини (варіанти) UA67748C2 (uk)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US5335197P	1997-07-22	1997-07-22
US5353597P	1997-07-23	1997-07-23
GBGB9717590.5A GB9717590D0 (en)	1997-08-20	1997-08-20	Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en)	1997-08-22	1997-08-22	Oral method for treating or preventing abnormal bone resorption
PCT/US1998/014796 WO1999004773A2 (en)	1997-07-22	1998-07-17	Method for inhibiting bone resorption

Publications (1)

Publication Number	Publication Date
UA67748C2 true UA67748C2 (uk)	2004-07-15

Family

ID=43743642

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000020982A UA67748C2 (uk)	1997-07-22	1998-07-17	Активний інгредієнт для виробництва лікарського засобу для інгібування резорбції кісткової тканини у людини (варіанти)

Country Status (5)

Country	Link
ME (1)	ME00862B (sr)
RS (1)	RS49979B (sr)
SI (1)	SI1175904T1 (sr)
TR (1)	TR200805763T2 (sr)
UA (1)	UA67748C2 (sr)

1998
- 1998-07-17 TR TR2008/05763T patent/TR200805763T2/xx unknown
- 1998-07-17 UA UA2000020982A patent/UA67748C2/uk unknown
- 1998-07-17 ME MEP-2000-18A patent/ME00862B/me unknown
- 1998-07-17 RS YUP-18/00A patent/RS49979B/sr unknown
- 1998-07-17 SI SI9830879T patent/SI1175904T1/sl unknown

Also Published As

Publication number	Publication date
YU1800A (sh)	2002-08-12
SI1175904T1 (sl)	2007-06-30
ME00862B (me)	2008-09-29
TR200805763T2 (tr)	2011-05-23
RS49979B (sr)	2008-09-29

Publication	Publication Date	Title
US5994329A (en)	1999-11-30	Method for inhibiting bone resorption
US6015801A (en)	2000-01-18	Method for inhibiting bone resorption
US6465443B2 (en)	2002-10-15	Method for inhibiting bone resorption
CA2294595C (en)	2001-08-21	Inhibiting bone resorption
GB2336311A (en)	1999-10-20	Bisphosphonate Dosing Regimen
AU741818B2 (en)	2001-12-13	Method for inhibiting bone resorption
MXPA00000789A (en)	2001-12-04	Method for inhibiting bone resorption
IL153109A (en)	2004-01-04	An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture
CA2349744A1 (en)	1999-02-04	Inhibition bone resorption
AU1567702A (en)	2002-04-11	Method for inhibiting bone resorption
HUP0004653A2 (hu)	2001-04-28	Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására
AU2451102A (en)	2002-05-02	Method for inhibiting bone resorption
RS49979B (sr)	2008-09-29	Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju